Skip to content
Isierige.com

Isierige.com

Unraveling Stories Connecting Communities

  • Home
  • Arts Entertainments
  • Auto
  • Business
  • Cryptocurrency
  • Digital Marketing
  • Education
  • Finance
  • Gaming
  • Health Fitness
  • Home Kitchen
  • Legal Law
  • Lifestyle Fashion
  • Medicine
  • Pets
  • Real Estate
  • Relationship
  • Shopping Product Reviews
  • Sports
  • Technology
  • Tours Travel
  • Privacy Policy
  • Contact US
  • Sitemap

Category: Medicine

Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
Medicine

Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma

adminMay 26, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com Key Takeaways from the BATURA Trial Airsupra Reduces Severe Exacerbations by 47%In the Phase IIIb…

Nerandomilast Meets Primary Endpoints in Phase III IPF and PPF Trials, Shows Significant Lung Function Preservation
Medicine

Nerandomilast Meets Primary Endpoints in Phase III IPF and PPF Trials, Shows Significant Lung Function Preservation

adminMay 25, 2025

Credit: mi_viri | stock.adobe.com Key Takeaways: Nerandomilast Phase III Trial Data Nerandomilast Demonstrates Statistically Significant FVC Preservation in IPF and…

The Role of AI in Solving Clinical Trial Diversity and Access Challenges
Medicine

The Role of AI in Solving Clinical Trial Diversity and Access Challenges

adminMay 25, 2025

In a recent video interview with Applied Clinical Trials, Michel van Harten, MD, CEO, myTomorrows, discussed the integration of artificial…

ARCHES and ENZAMET Trials Confirm Long-Term Xtandi Efficacy in Metastatic Hormone-Sensitive Prostate Cancer
Medicine

ARCHES and ENZAMET Trials Confirm Long-Term Xtandi Efficacy in Metastatic Hormone-Sensitive Prostate Cancer

adminMay 24, 2025

Credit: Dr_Microbe | stock.adobe.com. Key Takeaways: Xtandi in mHSPC Long-Term Survival Confirmed. Five-year results from the Phase III ARCHES trial…

Harnessing Technology and Adopting Unified Approaches to Optimize Pharmacovigilance Activities
Medicine

Harnessing Technology and Adopting Unified Approaches to Optimize Pharmacovigilance Activities

adminMay 24, 2025

Image Credit: © NicoElNino – stock.adobe.com Key takeaways Digital intake must be the default to ensure quality and efficiency: Prioritizing…

How AI Lowers the Real-World Barriers to Trial Participation
Medicine

How AI Lowers the Real-World Barriers to Trial Participation

adminMay 23, 2025

In a recent video interview with Applied Clinical Trials, Michel van Harten, MD, CEO, myTomorrows, discussed the integration of artificial…

Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
Medicine

Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data

adminMay 23, 2025

Image Credit: © Pixel-Shot – stock.adobe.com Key takeaways Susvimo sets a new standard for long-acting ophthalmic treatments: With FDA approval…

FDA Panel Votes Against Columvi-GemOx sBLA for R/R DLBCL Over Regional Data Concerns from STARGLO Trial
Medicine

FDA Panel Votes Against Columvi-GemOx sBLA for R/R DLBCL Over Regional Data Concerns from STARGLO Trial

adminMay 22, 2025May 22, 2025

Credit: Araki Illustrations | stock.adobe.com Key Takeaways FDA Panel Votes Against Columvi-GemOx sBLAThe FDA’s Oncologic Drugs Advisory Committee (ODAC) declined…

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
Medicine

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research

adminMay 22, 2025

Image Credit: © JHVEPhoto – stock.adobe.com Key takeaways Placebo-controlled trials now required for low-risk groups: FDA will require placebo-controlled trials…

Bridging Innovation and Trust with Artificial Intelligence
Medicine

Bridging Innovation and Trust with Artificial Intelligence

adminMay 21, 2025

In a recent video interview with Applied Clinical Trials, Michel van Harten, MD, CEO, myTomorrows, discussed the integration of artificial…

The Road to Simpler and Better Trials
Medicine

The Road to Simpler and Better Trials

adminMay 21, 2025

Image Credit: © photon_photo – stock.adobe.com Key takeaways Simplify with purpose: prioritize what adds value: Modern trials are overloaded with…

Monitoring NIH Funding Cuts
Medicine

Monitoring NIH Funding Cuts

adminMay 20, 2025

In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed…

Advancing Patient Engagement in Community-Based Oncology Research
Medicine

Advancing Patient Engagement in Community-Based Oncology Research

adminMay 20, 2025

Image Credit: © putilov_denis – stock.adobe.com Key Takeaways Community trials drive access and diversity: Embedding clinical trials in local oncology…

A Disruption in the Clinical Research Enterprise
Medicine

A Disruption in the Clinical Research Enterprise

adminMay 19, 2025

In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed…

KEYNOTE-B96 Trial Shows Keytruda is First Immunotherapy to Improve Overall Survival in Platinum-Resistant Ovarian Cancer
Medicine

KEYNOTE-B96 Trial Shows Keytruda is First Immunotherapy to Improve Overall Survival in Platinum-Resistant Ovarian Cancer

adminMay 18, 2025

Credit: MohammedElAmine | stock.adobe.com Key Takeaways from the Phase III KEYNOTE-B96/ENGOT-ov65 Trial Keytruda Shows First OS Benefit in Ovarian Cancer:…

How NIH Funding Cuts are Affecting Academic Research
Medicine

How NIH Funding Cuts are Affecting Academic Research

adminMay 18, 2025

In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed…

Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
Medicine

Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity

adminMay 17, 2025

Credit: GoodIdeas | stock.adobe.com Key Takeaways of the TAK-861-2001 Trial Clinically Meaningful Efficacy: In the Phase II TAK-861-2001 trial, oveporexton…

Phase II Data Land Merck’s Welireg FDA Approval for Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma
Medicine

Phase II Data Land Merck’s Welireg FDA Approval for Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma

adminMay 17, 2025

Image Credit: © JHVEPhoto – stock.adobe.com Key takeaways 1. Regulatory milestone for rare tumors: Merck’s Welireg received FDA approval for…

FDA Grants Accelerated Approval to AbbVie’s Emrelis for the Treatment of NSCLC Based on Phase II Trial Results
Medicine

FDA Grants Accelerated Approval to AbbVie’s Emrelis for the Treatment of NSCLC Based on Phase II Trial Results

adminMay 16, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com Key takeaways 1. Accelerated approval based on Phase II data: Emrelis received FDA accelerated approval…

A Closer Look at NIH Grant Terminations
Medicine

A Closer Look at NIH Grant Terminations

adminMay 16, 2025

In a recent video interview with Applied Clinical Trials, Michael Liu, medical student and researcher at Harvard Medical School, discussed…

3 Perspectives on Medical Research Funding Cuts
Medicine

3 Perspectives on Medical Research Funding Cuts

adminMay 15, 2025

The calendar year of 2025 has brought many new challenges to the clinical research industry. Earlier in the year, several…

Novo Nordisk’s Sogroya Demonstrates Favorable Outcomes in Phase III Trial for Children’s Growth Disorders
Medicine

Novo Nordisk’s Sogroya Demonstrates Favorable Outcomes in Phase III Trial for Children’s Growth Disorders

adminMay 14, 2025

Image Credit: © photon_photo – stock.adobe.com Novo Nordisk has shared positive trial results from the Phase III REAL8 basket study…

APHINITY Trial Shows Perjeta-Based Regimen Improves 10-Year Overall Survival in HER2-Positive Early Breast Cancer
Medicine

APHINITY Trial Shows Perjeta-Based Regimen Improves 10-Year Overall Survival in HER2-Positive Early Breast Cancer

adminMay 14, 2025

Credit: David A Litman | stock.adobe.com Long-term overall survival (OS) data from the Phase III APHINITY trial (NCT01358877) show a…

3 Common eCOA Implementation Challenges and How to Solve Them
Medicine

3 Common eCOA Implementation Challenges and How to Solve Them

adminMay 13, 2025

Image Credit: © putilov_denis – stock.adobe.com eCOA (electronic clinical outcome assessment) systems have become essential in modern clinical trials, offering…

Public Perception of Clinical Research Amidst Policy Changes
Medicine

Public Perception of Clinical Research Amidst Policy Changes

adminMay 13, 2025May 13, 2025

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of…

Four Strategic Considerations to Choose an EDC
Medicine

Four Strategic Considerations to Choose an EDC

adminMay 12, 2025

Image Credit: © putilov_denis – stock.adobe.com The role of electronic data capture (EDC) systems in clinical trials looks very different…

DESTINY-Breast11 Trial Shows Enhertu Plus THP Significantly Improves Response Rates in High-Risk HER2-Positive Early Breast Cancer
Medicine

DESTINY-Breast11 Trial Shows Enhertu Plus THP Significantly Improves Response Rates in High-Risk HER2-Positive Early Breast Cancer

adminMay 12, 2025

Credit: Valerii Apetroaiei | stock.adobe.com Topline results from the Phase III DESTINY-Breast11 trial (NCT05113251) show that Enhertu (trastuzumab deruxtecan; AstraZeneca…

Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial
Medicine

Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial

adminMay 11, 2025May 11, 2025

Credit: syahrir | stock.adobe.com Updated data from the pivotal Phase III ELATIVE trial (NCT04526665) show Iqirvo (elafibranor) significantly improved fatigue…

The Potential for Stricter Regulations in Vaccine Trials
Medicine

The Potential for Stricter Regulations in Vaccine Trials

adminMay 11, 2025

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of…

Imfinzi Regimen Demonstrates Positive, Meaningful Outcomes in Phase III Bladder Cancer Trial
Medicine

Imfinzi Regimen Demonstrates Positive, Meaningful Outcomes in Phase III Bladder Cancer Trial

adminMay 10, 2025

Image Credit: © Matthieu – stock.adobe.com AstraZeneca has shared positive results from its Phase III POTOMAC trial of Imfinzi (durvalumab)…

Linerixibat Demonstrates Statistically Significant Reduction in Pruritus in Phase III GLISTEN Trial for PBC
Medicine

Linerixibat Demonstrates Statistically Significant Reduction in Pruritus in Phase III GLISTEN Trial for PBC

adminMay 10, 2025May 10, 2025

Credit: Yurii Kibalnik | stock.adobe.com Top-line results from the Phase III GLISTEN trial (NCT04950127) show that the novel therapy linerixibat…

How Vaccine Trials Could be Affected by Potential Policy Changes
Medicine

How Vaccine Trials Could be Affected by Potential Policy Changes

adminMay 9, 2025May 9, 2025

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of…

Boehringer Announces Start of Phase II Geographic Atrophy Trial of Potential First-in-Class Therapy
Medicine

Boehringer Announces Start of Phase II Geographic Atrophy Trial of Potential First-in-Class Therapy

adminMay 9, 2025

Image Credit: © Pixel-Shot – stock.adobe.com Boehringer Ingelheim has announced the start of the JADE Phase II clinical trial (NCT06769048),…

Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
Medicine

Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus

adminMay 8, 2025May 8, 2025

Image Credit: © photon_photo – stock.adobe.com Gilead has announced final data from its Phase III MYR301 clinical trial of bulevirtide…

Unifying Industry to Better Understand GCP Guidance
Medicine

Unifying Industry to Better Understand GCP Guidance

adminMay 8, 2025

David Nickerson, head of clinical quality management at EMD Serono, executive sponsor of TransCelerate’s ICH E6(R3) Initiative & PhRMA topic…

Phase III MUSA Trial Finds Similar Six-Month Outcomes Between Botox, Midurethral Sling in Patients with Mixed Urinary Incontinence
Medicine

Phase III MUSA Trial Finds Similar Six-Month Outcomes Between Botox, Midurethral Sling in Patients with Mixed Urinary Incontinence

adminMay 7, 2025

Credit: ibreakstock | stock.adobe.com Results from the Phase III MUSA trial show that in women with moderate to severe mixed…

Nanobiotix Shares Positive Data from MD Anderson-Led Phase I Study in Pancreatic Cancer
Medicine

Nanobiotix Shares Positive Data from MD Anderson-Led Phase I Study in Pancreatic Cancer

adminMay 7, 2025

Image Credit: © Matthieu – stock.adobe.com Nanobiotix has announced full results from a Phase I study evaluating its novel therapy,…

QUASAR LTE Trial Shows Tremfya Produces Sustained Clinical, Endoscopic Remission Through 92 Weeks in Ulcerative Colitis
Medicine

QUASAR LTE Trial Shows Tremfya Produces Sustained Clinical, Endoscopic Remission Through 92 Weeks in Ulcerative Colitis

adminMay 6, 2025May 6, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com Long-term extension (LTE) data from the Phase IIb/III QUASAR trial (NCT04033445) program show adult patients…

AstraZeneca’s Breztri Meets Primary Endpoints in Duo of Phase III Asthma Trials
Medicine

AstraZeneca’s Breztri Meets Primary Endpoints in Duo of Phase III Asthma Trials

adminMay 6, 2025

Image Credit: © Sebastian Kaulitzki – stock.adobe.com AstraZeneca has announced positive results from the Phase III KALOS and LOGOS clinical…

Challenges in Bringing Effective Therapies to Cancer Patients
Medicine

Challenges in Bringing Effective Therapies to Cancer Patients

adminMay 5, 2025

In a recent video interview with Applied Clinical Trials, C.K. Wang, MD, chief medical officer, COTA, discussed a recent study…

Unlock Commercial Growth through Data-Driven Patient and HCP Insights
Medicine

Unlock Commercial Growth through Data-Driven Patient and HCP Insights

adminMay 4, 2025

Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies…

The Growing Roles of RWD and RWE in Oncology
Medicine

The Growing Roles of RWD and RWE in Oncology

adminMay 4, 2025May 4, 2025

In a recent video interview with Applied Clinical Trials, C.K. Wang, MD, chief medical officer, COTA, discussed a recent study…

Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
Medicine

Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial

adminMay 3, 2025May 3, 2025

Credit: Peter Hansen | stock.adobe.com Weekly semaglutide was found to significantly improve steatohepatitis and fibrosis while enhancing metabolic markers and…

Improving Clinical Trial Reporting with CONSORT 2025 Updates
Medicine

Improving Clinical Trial Reporting with CONSORT 2025 Updates

adminMay 3, 2025

Image Credit: © photon_photo – stock.adobe.com Clinical trials are responsible for generating some of the most important evidence in evaluating…

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast
Medicine

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

adminMay 2, 2025

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

FDA Approves Satsuma’s STS101 Nasal Powder for Acute Migraine
Medicine

FDA Approves Satsuma’s STS101 Nasal Powder for Acute Migraine

adminMay 2, 2025

Image Credit: © yodiyim – stock.adobe.com The FDA has approved Satsuma’s STS101 dihydroergotamine (DHE) nasal powder under the name of…

MATINEE Trial Shows Nucala Significantly Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation on Triple Therapy
Medicine

MATINEE Trial Shows Nucala Significantly Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation on Triple Therapy

adminMay 1, 2025

Credit: peterschreiber.media | stock.adobe.com Results of the Phase III MATINEE trial (NCT04133909) show that Nucala (mepolizumab) produced a significant reduction…

Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
Medicine

Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis

adminMay 1, 2025May 1, 2025

Credit: Yurii Kibalnik | stock.adobe.com The FDA has approved AbbVie’s Rinvoq (upadacitinib) 15 mg once daily for the treatment of…

FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
Medicine

FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis

adminApril 30, 2025

Image Credit: © JHVEPhoto – stock.adobe.com The FDA has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for the treatment of treatment…

New Zongertinib Data from Boehringer Shows Sustained, Clinically Meaningful Results in Advanced NSCLC Patients
Medicine

New Zongertinib Data from Boehringer Shows Sustained, Clinically Meaningful Results in Advanced NSCLC Patients

adminApril 30, 2025April 30, 2025

Image Credit: © Sebastian Kaulitzki – stock.adobe.com Boehringer Ingelheim has shared new data from the Phase Ib Beamion LUNG-1 clinical…

Johnson & Johnson’s TAR-200 for Bladder Cancer Shows High Rates of Disease-Free Survival, Bladder Preservation
Medicine

Johnson & Johnson’s TAR-200 for Bladder Cancer Shows High Rates of Disease-Free Survival, Bladder Preservation

adminApril 29, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com Early interim data from cohort 4 of the Phase IIb SunRISe-1 trial (NCT04640623) evaluating the…

Pivotal Phase III Trial Data Show Pfizer’s Sasanlimab with BCG Significantly Improves Event-Free Survival in Bladder Cancer
Medicine

Pivotal Phase III Trial Data Show Pfizer’s Sasanlimab with BCG Significantly Improves Event-Free Survival in Bladder Cancer

adminApril 29, 2025

Image Credit: © Matthieu – stock.adobe.com Pfizer has shared new data from the Phase III CREST clinical trial of sasanlimab…

Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
Medicine

Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC

adminApril 28, 2025

Credit: Lars Neumann | stock.adobe.com Interim data from the Phase III KEYNOTE-689 trial (NCT03765918) show that perioperative treatment with Keytruda…

Elevated Kitting Strategies for Clinical Trials
Medicine

Elevated Kitting Strategies for Clinical Trials

adminApril 28, 2025

Industry experts from Precision for Medicine will share practical strategies for navigating the complexities of sample management in early-phase trials.…

Bridging the Gap Between Legacy Measures and Contemporary Healthcare
Medicine

Bridging the Gap Between Legacy Measures and Contemporary Healthcare

adminApril 27, 2025April 27, 2025

Image Credit: © photon_photo – stock.adobe.com Patient-reported outcomes (PROs) have long served as an essential tool for understanding how patients…

Understanding the True Meaning of Risk in Clinical Trial Operations
Medicine

Understanding the True Meaning of Risk in Clinical Trial Operations

adminApril 27, 2025

In a recent video interview with Applied Clinical Trials, Rob Jones, product manager, TMF practice area, Pharmalex, discussed challenges in…

The Importance of Clinical Trial Oversight when Outsourcing
Medicine

The Importance of Clinical Trial Oversight when Outsourcing

adminApril 26, 2025April 26, 2025

In a recent video interview with Applied Clinical Trials, Rob Jones, product manager, TMF practice area, Pharmalex, discussed challenges in…

Phase III Trial Data Show Roche’s Xofluza Significantly Reduces Flu Transmission
Medicine

Phase III Trial Data Show Roche’s Xofluza Significantly Reduces Flu Transmission

adminApril 26, 2025

Image Credit: © Dr_Microbe – stock.adobe.com Roche has shared additional findings from the Phase III CENTERSTONE clinical trial of Xofluza…

Phase II Advance-HTN Trial Shows Lorundrostat Significantly Lowers Blood Pressure in Treatment-Resistant Hypertension
Medicine

Phase II Advance-HTN Trial Shows Lorundrostat Significantly Lowers Blood Pressure in Treatment-Resistant Hypertension

adminApril 25, 2025April 25, 2025

Credit: Andrey Popov | stock.adobe.com Findings from the 12-week Phase II Advance-HTN trial (NCT05769608) show that lorundrostat significantly lowered systolic blood…

Embracing Risk-Based Approaches with Clinical Trial Oversight
Medicine

Embracing Risk-Based Approaches with Clinical Trial Oversight

adminApril 25, 2025

In a recent video interview with Applied Clinical Trials, Rob Jones, product manager, TMF practice area, Pharmalex, discussed challenges in…

Phase III ASPEN Trial Shows Brensocatib Reduces Exacerbations, Lung Function Decline in Bronchiectasis
Medicine

Phase III ASPEN Trial Shows Brensocatib Reduces Exacerbations, Lung Function Decline in Bronchiectasis

adminApril 24, 2025

Credit: Thipphaphone | stock.adobe.com Brensocatib was found to significantly lower the annualized rate of pulmonary exacerbations and lung function decline…

Cobenfy Falls Short of Statistical Significance as Additional Treatment for Schizophrenia in Phase III Clinical Trial
Medicine

Cobenfy Falls Short of Statistical Significance as Additional Treatment for Schizophrenia in Phase III Clinical Trial

adminApril 24, 2025April 24, 2025

Image Credit: © freshidea – stock.adobe.com Bristol Myers Squibb has shared results from its Phase III ARISE trial evaluating Cobenfy…

Rinvoq Shows Superior Remission Rates in Giant-Cell Arteritis With Reduced Steroid Use, Phase III Trial Finds
Medicine

Rinvoq Shows Superior Remission Rates in Giant-Cell Arteritis With Reduced Steroid Use, Phase III Trial Finds

adminApril 23, 2025

Credit: Yurii Kibalnik | stock.adobe.com A regimen of Rinvoq (upadacitinib) with a 26-week glucocorticoid taper showed superior efficacy in producing…

A Roadmap for the Use of Artificial Intelligence in Managing Trial Master Files
Medicine

A Roadmap for the Use of Artificial Intelligence in Managing Trial Master Files

adminApril 23, 2025

In a recent video interview with Applied Clinical Trials, Rob Jones, product manager, TMF practice area, Pharmalex, discussed challenges in…

Tolebrutinib Falls Short of Superiority vs. Aubagio Treating Relapsing Multiple Sclerosis in GEMINI Trials
Medicine

Tolebrutinib Falls Short of Superiority vs. Aubagio Treating Relapsing Multiple Sclerosis in GEMINI Trials

adminApril 22, 2025April 22, 2025

Credit: freshidea | stock.adobe.com Data from the Phase III GEMINI 1 (NCT04410978) and GEMINI 2 trials (NCT04410991) show that compared to…

DESTINY-Breast09 Trial Shows Enhertu Plus Perjeta Significantly Improves Survival in HER2-Positive Metastatic Breast Cancer
Medicine

DESTINY-Breast09 Trial Shows Enhertu Plus Perjeta Significantly Improves Survival in HER2-Positive Metastatic Breast Cancer

adminApril 22, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com Interim data from the Phase III DESTINY-Breast09 trial (NCT04784715) found that the combination of Enhertu…

Gilead’s Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Medicine

Gilead’s Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1-Positive Metastatic Triple-Negative Breast Cancer

adminApril 21, 2025

Image Credit: Adobe Stock Images/Lars Neumann Topline findings from Gilead’s Phase III ASCENT-04/KEYNOTE-D19 study found that the combination of Trodelvy…

Bridging Data & Disparities: The Power of SDOH in the Life Sciences Industry
Medicine

Bridging Data & Disparities: The Power of SDOH in the Life Sciences Industry

adminApril 21, 2025April 21, 2025

Bridging Data & Disparities: The Power of SDOH in the Life Sciences Industry

Bringing the Rare Disease Community Together
Medicine

Bringing the Rare Disease Community Together

adminApril 20, 2025

In a recent video interview with Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical…

Improving Relationships and Diversifying the Site Selection Process
Medicine

Improving Relationships and Diversifying the Site Selection Process

adminApril 20, 2025

In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number…

Leading the Technology and Innovation Front Through Rare Disease Research
Medicine

Leading the Technology and Innovation Front Through Rare Disease Research

adminApril 19, 2025April 19, 2025

In a recent video interview with Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical…

Alector Completes Enrollment for Phase II Trial of Investigational Alzheimer’s Disease Therapy
Medicine

Alector Completes Enrollment for Phase II Trial of Investigational Alzheimer’s Disease Therapy

adminApril 19, 2025

Image Credit: © Aerial Mike – stock.adobe.com Alector has announced the completion of enrollment for its Phase II clinical trial,…

Uplizna Shows Significant Efficacy, Safety Treating Generalized Myasthenia Gravis in Phase III MINT Trial
Medicine

Uplizna Shows Significant Efficacy, Safety Treating Generalized Myasthenia Gravis in Phase III MINT Trial

adminApril 18, 2025April 18, 2025

Credit: wutipong | stock.adobe.com Findings from the Phase III MINT clinical trial (NCT04524273) show that Uplizna (inebilizumab) produced significant short-term…

Eli Lilly’s Oral GLP-1, Orforglipron, Demonstrates Efficacy and Safety Consistent with Injectable GLP-1s in Phase III Trial
Medicine

Eli Lilly’s Oral GLP-1, Orforglipron, Demonstrates Efficacy and Safety Consistent with Injectable GLP-1s in Phase III Trial

adminApril 18, 2025April 18, 2025

Image Credit: © Mnt – stock.adobe.com Eli Lilly has shared positive Phase III clinical trial data of its investigational, oral…

FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
Medicine

FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial

adminApril 17, 2025

Credit: MarijaBazarova | stock.adobe.com Long-term safety and efficacy clinical trial data (NCT03307980) for patients with hemophilia B administered the recombinant…

Clinical Strategies to Optimize Software as a Medical Device to treat Mental Health
Medicine

Clinical Strategies to Optimize Software as a Medical Device to treat Mental Health

adminApril 17, 2025

Devin Ridgley, PhD, Director, Project Management, Medical Device and Diagnostics Research, ICON JoAnne Bronikowski, BSCS, RAC, Senior Manager, Regulatory Affairs,…

DapaTAVI Trial Shows Farxiga Significantly Lowers Risk of Death After Transcatheter Aortic-Valve Implantation in Older Patients
Medicine

DapaTAVI Trial Shows Farxiga Significantly Lowers Risk of Death After Transcatheter Aortic-Valve Implantation in Older Patients

adminApril 16, 2025April 16, 2025

Credit: blacksalmon | stock.adobe.com Results from the Phase IV DapaTAVI trial (NCT04696185) show that the addition of Farxiga (dapagliflozin) to…

Johnson & Johnson’s Icotrokinra Succeeds in Phase III Trial for Plaque Psoriasis in Adolescents
Medicine

Johnson & Johnson’s Icotrokinra Succeeds in Phase III Trial for Plaque Psoriasis in Adolescents

adminApril 16, 2025April 16, 2025

Credit: Milan Lipowski | stock.adobe.com Johnson & Johnson has shared positive data from a subgroup analysis of the Phase III…

Phase III HERCULES Trial Shows Tolebrutinib Significantly Slows Disability Progression in Non-Relapsing Secondary Progressive MS
Medicine

Phase III HERCULES Trial Shows Tolebrutinib Significantly Slows Disability Progression in Non-Relapsing Secondary Progressive MS

adminApril 15, 2025

Credit: ralwel | stock.adobe.com Findings from the Phase III HERCULES trial (NCT04411641) published by The New England Journal of Medicine…

Unique Challenges in Rare Disease Research
Medicine

Unique Challenges in Rare Disease Research

adminApril 15, 2025

In a recent video interview with Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical…

Phase III EXPECTS Trial Finds Alteplase Boosts 90-Day Recovery in Posterior Circulation Stroke Patients
Medicine

Phase III EXPECTS Trial Finds Alteplase Boosts 90-Day Recovery in Posterior Circulation Stroke Patients

adminApril 14, 2025

Credit: Iqbal | stock.adobe.com Findings from the Phase III EXPECTS clinical trial (NCT05429476) show that in patients experiencing a mostly…

Patient Centricity, Data Collection, and the Role of AI
Medicine

Patient Centricity, Data Collection, and the Role of AI

adminApril 14, 2025

February 13th 2025 Article Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part…

Sustainability by Design
Medicine

Sustainability by Design

adminApril 13, 2025

In a recent video interview with Applied Clinical Trials, Theirry Escudier, Portfolio Lead, Pistoia Alliance, discussed the alliance’s newest initiative…

Maintaining Regulatory Adherence with Clinical Technology
Medicine

Maintaining Regulatory Adherence with Clinical Technology

adminApril 13, 2025

In a recent video interview with Applied Clinical Trials, Theirry Escudier, Portfolio Lead, Pistoia Alliance, discussed the alliance’s newest initiative…

What’s Next for DEI?
Medicine

What’s Next for DEI?

adminApril 12, 2025April 12, 2025

Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and…

April 2025 Interactive Digital Edition
Medicine

April 2025 Interactive Digital Edition

adminApril 12, 2025

Applied Clinical Trials: April 2025 Interactive Digital Edition The Impact of DEI Ban On Clinical Research Ecosystem Tapping the Patient…

The Impact of DEI Ban On Clinical Research Ecosystem
Medicine

The Impact of DEI Ban On Clinical Research Ecosystem

adminApril 11, 2025

Rebecca Johnson, PhD, Clinical Research Recruitment and Inclusion Executive and Strategist Efforts to make sustainable change toward more inclusive clinical…

Tapping the Patient Voice as a Strategic Differentiator
Medicine

Tapping the Patient Voice as a Strategic Differentiator

adminApril 11, 2025April 11, 2025

Stacy Hurt, Chief Patient Officer, Parexel As a patient advocate and caregiver, I’m excited and bullish about the significant progress…

Benchmarking Risks Across Therapeutic Areas
Medicine

Benchmarking Risks Across Therapeutic Areas

adminApril 10, 2025

Image Credit: © Murrstock – stock.adobe.com The monitoring of key risk indicators (KRIs) is an established form of risk control…

Scaling eSource-Enabled Clinical Trials: Hospital Perspectives
Medicine

Scaling eSource-Enabled Clinical Trials: Hospital Perspectives

adminApril 10, 2025

Oncology clinical trials are increasingly complex, driven by rising data volumes, regulatory requirements, and inefficiencies in manual data handling. Current…

The Hard Truth About Rare Disease and Gene Therapy Drug Development
Medicine

The Hard Truth About Rare Disease and Gene Therapy Drug Development

adminApril 9, 2025

Ken Getz, MBA, Executive Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine…

What’s Next for Digital Patient Engagement?
Medicine

What’s Next for Digital Patient Engagement?

adminApril 9, 2025April 9, 2025

Hugo Stephenson, MD, Co-Founder and Executive Chair, TrialScreen With 40% of young people now getting their news from platforms such…

What’s in it for Patients?
Medicine

What’s in it for Patients?

adminApril 8, 2025

Digital measures offer new insights into human health but require complex, multi-stakeholder development. Are they worth the effort? Can they…

High-Dose Ocrevus Falls Short of Primary Endpoint in Relapsing Multiple Sclerosis Trial
Medicine

High-Dose Ocrevus Falls Short of Primary Endpoint in Relapsing Multiple Sclerosis Trial

adminApril 8, 2025

Credit: ralwel | stock.adobe.com Roche has announced results from the Phase III MUSETTE clinical trial of high-dose Ocrevus (ocrelizumab) intravenous…

Topline Results from Phase IIIb APEX Trial Shows Efficacy of Tremfya for Active Psoriatic Arthritis
Medicine

Topline Results from Phase IIIb APEX Trial Shows Efficacy of Tremfya for Active Psoriatic Arthritis

adminApril 7, 2025

Credit: fusssergei | stock.adobe.com Findings from the Phase IIIb APEX trial (NCT04882098) found that Tremfya (guselkumab) produced a significant reduction…

Addressing Current Regulatory Challenges with Diversity in Clinical Trials
Medicine

Addressing Current Regulatory Challenges with Diversity in Clinical Trials

adminApril 7, 2025

In a recent video interview with Applied Clinical Trials, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discussed the…

Resource Reallocation in Clinical Research
Medicine

Resource Reallocation in Clinical Research

adminApril 6, 2025

In a recent video interview with Applied Clinical Trials, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discussed the…

Industry’s Response to Recent Government Research Changes
Medicine

Industry’s Response to Recent Government Research Changes

adminApril 6, 2025

In a recent video interview with Applied Clinical Trials, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discussed the…

Filling the Void for Clinical Research Leadership Amidst Political Headwinds
Medicine

Filling the Void for Clinical Research Leadership Amidst Political Headwinds

adminApril 5, 2025

In a recent video interview with Applied Clinical Trials, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discussed the…

Areas of Focus for Clinical Operations Leaders in the Current Research Climate
Medicine

Areas of Focus for Clinical Operations Leaders in the Current Research Climate

adminApril 5, 2025

In a recent video interview with Applied Clinical Trials, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discussed the…

Thermocool Smarttouch SF Catheter Demonstrates High Efficacy in Patients with Atrial Fibrillation
Medicine

Thermocool Smarttouch SF Catheter Demonstrates High Efficacy in Patients with Atrial Fibrillation

adminApril 4, 2025

Image Credit: © ckybe – stock.adobe.com One-year data from the SmartfIRE trial show that Johnson & Johnson’s (J&J) dual energy…

What Does Racial Color-Blindness Mean for Clinical Trial Participation?
Medicine

What Does Racial Color-Blindness Mean for Clinical Trial Participation?

adminApril 4, 2025April 4, 2025

Image Credit: © Jakub Krechowicz – stock.adobe.com Healthcare research represents a frontier where new drugs, behavioral interventions, diagnostics, and screening…

SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
Medicine

SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes

adminApril 3, 2025

Credit: santoelia | stock.adobe.com Results from the Phase III SOUL trial (NCT03914326) published by The New England Journal of Medicine…

Palatin Announces Results from Phase II Obesity Study of MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Medicine

Palatin Announces Results from Phase II Obesity Study of MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

adminApril 3, 2025

Image Credit: © Egor – stock.adobe.com Palatin has announced positive results from its BMT-801 Phase II clinical trial of co-administered…

API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients
Medicine

API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients

adminApril 2, 2025April 2, 2025

Credit: Artur | stock.adobe.com Findings from the Phase III API-CAT trial (NCT03692065) show that extended anticoagulant therapy with reduced-dose Eliquis…

Merck Shares Results from Phase III Clinical Trial of Winrevair in Pulmonary Arterial Hypertension
Medicine

Merck Shares Results from Phase III Clinical Trial of Winrevair in Pulmonary Arterial Hypertension

adminApril 2, 2025

Image Credit: © photon_photo – stock.adobe.com Merck has announced positive results from the Phase III ZENITH clinical trial of Winrevair…

Novel PCSK9 Inhibitor Achieves Significant Reduction in LDL Cholesterol Levels in Phase IIb Trial
Medicine

Novel PCSK9 Inhibitor Achieves Significant Reduction in LDL Cholesterol Levels in Phase IIb Trial

adminApril 1, 2025

Credit: Rasi | stock.adobe.com Data from the Phase IIb PURSUIT trial (NCT06173570) found that AZD0780, a novel proprotein convertase subtilisin–kexin…

Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
Medicine

Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda

adminApril 1, 2025

Image Credit: © putilov_denis – stock.adobe.com Merck has shared data from the 3475A-D77 Phase III clinical trial of the subcutaneous…

Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
Medicine

Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions

adminMarch 31, 2025March 31, 2025

Credit: Chudapa | stock.adobe.com Results from the Phase II ALPACA trial (NCT05565742) published by The New England Journal of Medicine…

Reliance on Traditional Research Methods
Medicine

Reliance on Traditional Research Methods

adminMarch 31, 2025March 31, 2025

In a recent video interview with Applied Clinical Trials, Rachael Higgins, chief commercial officer, PicnicHealth, discussed the company’s recently released…

The Leap from Deterministic to AI-Powered Stochastic Methods
Medicine

The Leap from Deterministic to AI-Powered Stochastic Methods

adminMarch 30, 2025March 30, 2025

Credit: ra2 studio | stock.adobe.com Clinical data is the cornerstone of progress in high-stakes pharmaceutical research and development. This vital…

Executing with Clinical Technology
Medicine

Executing with Clinical Technology

adminMarch 30, 2025

In a recent video interview with Applied Clinical Trials, Rachael Higgins, chief commercial officer, PicnicHealth, discussed the company’s recently released…

MITIGATE Trial Shows Uplizna Significantly Lowers Flare Risk, Glucocorticoid Dependence in IgG4-Related Disease
Medicine

MITIGATE Trial Shows Uplizna Significantly Lowers Flare Risk, Glucocorticoid Dependence in IgG4-Related Disease

adminMarch 29, 2025March 29, 2025

Credit: Naeblys | stock.adobe.com Findings from the Phase III MITIGATE trial (NCT04540497) show the efficacy of Uplizna (inebilizumab) in lowering…

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Medicine

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto

adminMarch 29, 2025March 29, 2025

Image Credit: © Dr_Microbe – stock.adobe.com The FDA has approved Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for…

The Impact of Funding Cuts on Medical Research
Medicine

The Impact of Funding Cuts on Medical Research

adminMarch 28, 2025

In a recent video interview with Applied Clinical Trials, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discussed the…

Addressing Clinical Trial Challenges Through AI and Scalable Solutions
Medicine

Addressing Clinical Trial Challenges Through AI and Scalable Solutions

adminMarch 28, 2025March 28, 2025

ACT: What advancements do you foresee for Medable AI and Medable Studio, and how might these innovations change the way…

FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
Medicine

FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults

adminMarch 27, 2025

Credit: adrian_ilie825 | stock.adobe.com Findings from the Phase III FOCUS trial (NCT05972044) show solriamfetol produced a significant reduction in the…

Johnson & Johnson Releases New Data from Phase III MARIPOSA Trial of Rybrevant-Lazcluze Combination in Non-Small Cell Lung Cancer
Medicine

Johnson & Johnson Releases New Data from Phase III MARIPOSA Trial of Rybrevant-Lazcluze Combination in Non-Small Cell Lung Cancer

adminMarch 27, 2025March 27, 2025

Image Credit: © iDoPixBox – stock.adobe.com Johnson & Johnson has shared new, positive data from the Phase III MARIPOSA clinical…

Addressing Data and Patient Retention Challenges
Medicine

Addressing Data and Patient Retention Challenges

adminMarch 26, 2025

In a recent video interview with Applied Clinical Trials, Rachael Higgins, chief commercial officer, PicnicHealth, discussed the company’s recently released…

Medable Eyes Expanded Presence in Europe with New Approval for Digital Trials
Medicine

Medable Eyes Expanded Presence in Europe with New Approval for Digital Trials

adminMarch 26, 2025

ACT: Medable has played a pivotal role in decentralized and digital clinical trials globally. How do you see the company…

Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
Medicine

Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS

adminMarch 25, 2025

Credit: ralwel | stock.adobe.com Results from the Phase III HERCULES (NCT04411641) trial and Phase III GEMINI 1 (NCT04410978) and GEMINI…

Understanding Study Coordinator Work Quality
Medicine

Understanding Study Coordinator Work Quality

adminMarch 25, 2025

The quality of study coordinator work is important to investigative sites, study sponsors, CROs, regulators, and patients. Site quality management…

VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
Medicine

VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer

adminMarch 24, 2025

Credit: Axel Kock | stock.adobe.com Data from the Phase III VERITAC-2 trial (NCT05654623) found that vepdegestrant (ARV-471) monotherapy produced a…

The Role of Quality Data in Utilizing Machine Learning Models
Medicine

The Role of Quality Data in Utilizing Machine Learning Models

adminMarch 24, 2025March 24, 2025

In a recent video interview with Applied Clinical Trials, Cameron Breze, product manager, Inovalon, discussed challenges in patient recruitment for…

The Impact on Drug Discovery
Medicine

The Impact on Drug Discovery

adminMarch 23, 2025

Credit: bizoo_n | stock.adobe.com The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset…

Connecting the Right Patients to the Right Trial
Medicine

Connecting the Right Patients to the Right Trial

adminMarch 23, 2025

February 13th 2025 Article Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part…

Tecentriq Falls Short of Primary Endpoint in IMvoke010 Trial for Locally Advanced Head and Neck Cancer
Medicine

Tecentriq Falls Short of Primary Endpoint in IMvoke010 Trial for Locally Advanced Head and Neck Cancer

adminMarch 22, 2025

Credit: urwa | stock.adobe.com Maintenance treatment with Tecentriq (atezolizumab) was not found to produce a significant improvement in event-free survival…

The Backbone of Innovation: High Quality Datasets
Medicine

The Backbone of Innovation: High Quality Datasets

adminMarch 22, 2025

Paul Mancinelli, PhD, is the Chief Technology Officer of WCG In today’s rapidly evolving technological landscape, robust datasets have become…

Enhancing Patient Engagement and Data Accuracy in Decentralized Trials
Medicine

Enhancing Patient Engagement and Data Accuracy in Decentralized Trials

adminMarch 21, 2025March 21, 2025

ACT: Medable has achieved impressive results, such as 90% eCOA adherence. How do you ensure such high levels of participant…

Novartis Shares Positive Phase III Data for Spinal Muscular Atrophy Therapy
Medicine

Novartis Shares Positive Phase III Data for Spinal Muscular Atrophy Therapy

adminMarch 21, 2025March 21, 2025

Image Credit: © Rochu_2008 – stock.adobe.com Novartis has announced positive results from its Phase III clinical trial program evaluating intrathecal…

Determining the Effectiveness of Decentralization Across Different Trials
Medicine

Determining the Effectiveness of Decentralization Across Different Trials

adminMarch 20, 2025

In a recent video interview with Applied Clinical Trials, Cameron Breze, product manager, Inovalon, discussed challenges in patient recruitment for…

Immunovant’s Batoclimab Excels in Clinical Trials for Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Medicine

Immunovant’s Batoclimab Excels in Clinical Trials for Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

adminMarch 20, 2025

Image Credit: Adobe Stock Images/Lila Patel Immunovant has shared positive results of its batoclimab in a Phase III clinical trial…

Phase III DIPPER Trial Shows Camrelizumab Boosts Event-Free Survival in Advanced Nasopharyngeal Carcinoma
Medicine

Phase III DIPPER Trial Shows Camrelizumab Boosts Event-Free Survival in Advanced Nasopharyngeal Carcinoma

adminMarch 19, 2025

Credit: Matthieu | stock.adobe.com Findings from the Phase III DIPPER trial (NCT03427827) published by JAMA show that adjuvant camrelizumab administered…

An Underrepresented Group in Clinical Trials
Medicine

An Underrepresented Group in Clinical Trials

adminMarch 19, 2025March 19, 2025

Kristin Tolbert, Associate VP of Health Equity Strategy at Jumo Health Pregnant women have long been excluded from clinical trials.…

Phase II DAHLIAS Trial Results Lead to Fast Track Designation for Nipocalimab for Sjögren’s Disease
Medicine

Phase II DAHLIAS Trial Results Lead to Fast Track Designation for Nipocalimab for Sjögren’s Disease

adminMarch 18, 2025March 18, 2025

Credit: Yurii Kibalnik | stock.adobe.com Based on data from the Phase II DAHLIAS (NCT04968912) trial, the FDA has granted Fast…

Genmab’s Rinatabart Sesutecan Continues Success in Advanced Ovarian Cancer Clinical Trials
Medicine

Genmab’s Rinatabart Sesutecan Continues Success in Advanced Ovarian Cancer Clinical Trials

adminMarch 18, 2025March 18, 2025

Image Credit: © Dr_Microbe – stock.adobe.com Genmab has shared positive results from the Phase I/II RAINFOL-01 clinical trial showing that…

Integrated Multi-Omic Data: Powering Precision Medicine
Medicine

Integrated Multi-Omic Data: Powering Precision Medicine

adminMarch 17, 2025

Credit: Toowongsa | stock.adobe.com Precision medicine is poised to transform healthcare as we’ve known it, from the earliest R&D efforts…

POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
Medicine

POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis

adminMarch 17, 2025

Credit: Milan Lipowski | stock.adobe.com Findings from the Phase III POETYK PsA-2 trial (NCT04908189) show Sotyktu (deucravacitinib) produced a significant…

Pooled Clinical Trial Meta-Analysis Shows Superior Response Rates with Padcev Plus Keytruda Treating Metastatic Urothelial Carcinoma
Medicine

Pooled Clinical Trial Meta-Analysis Shows Superior Response Rates with Padcev Plus Keytruda Treating Metastatic Urothelial Carcinoma

adminMarch 16, 2025

Credit: Lisa | stock.adobe.com A meta-analysis of 11 randomized and nonrandomized clinical trials shows significant benefits with Padcev (enfortumab vedotin-ejfv)…

Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Medicine

Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option

adminMarch 16, 2025

Credit: RAJCREATIONZS | stock.adobe.com Results from an ongoing Phase I trial have shown the potential of once-yearly intramuscular administration of…

Phase III Trial Finds Baricitinib Boosts Hair Regrowth in Adolescents With Severe Alopecia Areata
Medicine

Phase III Trial Finds Baricitinib Boosts Hair Regrowth in Adolescents With Severe Alopecia Areata

adminMarch 15, 2025

Credit: Alex Papp | stock.adobe.com Data from the Phase III BRAVE-AA-PEDS (NCT05723198) trial show that adolescents with severe alopecia areata (AA)…

Collaborative Strategies for Technology Integration in Clinical Studies
Medicine

Collaborative Strategies for Technology Integration in Clinical Studies

adminMarch 15, 2025

Image Credit: © putilov_denis – stock.adobe.com Digital technologies have significantly transformed the landscape of clinical trials, revolutionizing the way they…

Leading with the Patient Voice
Medicine

Leading with the Patient Voice

adminMarch 14, 2025March 14, 2025

In a recent video interview with Applied Clinical Trials, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced…

Doravirine/Islatravir Regimen Shows Promise in Multiple Phase III Trials for the Treatment of HIV
Medicine

Doravirine/Islatravir Regimen Shows Promise in Multiple Phase III Trials for the Treatment of HIV

adminMarch 14, 2025

Image Credit: © Ezume Images – stock.adobe.com Merck has announced positive results from two Phase III clinical trials of the…

Streamlining Patient Recruitment with Technology
Medicine

Streamlining Patient Recruitment with Technology

adminMarch 13, 2025

In a recent video interview with Applied Clinical Trials, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced…

Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Medicine

Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis

adminMarch 13, 2025

Image Credit: © Sebastian Kaulitzki – stock.adobe.com Johnson & Johnson has shared positive results from multiple clinical trials of icotrokinra…

Strategies to Improve Patient Engagement
Medicine

Strategies to Improve Patient Engagement

adminMarch 12, 2025

In a recent video interview with Applied Clinical Trials, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced…

Aiming to Calculate, Accommodate, and Innovate for Enhanced Drug Development
Medicine

Aiming to Calculate, Accommodate, and Innovate for Enhanced Drug Development

adminMarch 12, 2025

Zahiah (Zee Zee) Gueddar, Senior Director, Commercialization, IQVIA Technologies Melissa Mooney, Director Solution Engineering, IQVIA Patient Suite, IQVIA Technologies Katie Shaw,…

Accelerating Drug Development with Faster Patient Enrollment
Medicine

Accelerating Drug Development with Faster Patient Enrollment

adminMarch 11, 2025

In a recent video interview with Applied Clinical Trials, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced…

It’s Time for the Life Sciences Industry to Accelerate Action for Gender Equality
Medicine

It’s Time for the Life Sciences Industry to Accelerate Action for Gender Equality

adminMarch 11, 2025March 11, 2025

Vicky Marriott, Head of Statistics at Phastar As we marked International Women’s Day on March 8, we all need to…

A New Era for Faster, Smarter Clinical Trials
Medicine

A New Era for Faster, Smarter Clinical Trials

adminMarch 10, 2025March 10, 2025

Image Credit: © photon_photo – stock.adobe.com Obstacles for pharma, biotech, and CROs Contract research organizations (CROs), biotech companies, and pharmaceutical…

Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
Medicine

Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps

adminMarch 10, 2025

Credit: Prostock-studio | stock.adobe.com Tezspire (tezepelumab-ekko; Amgen and AstraZeneca) was found to significantly decrease the size of nasal polyps while…

Analysis of KEYNOTE-A18 Trial Finds Keytruda is Not Cost-Effective at Current Prices
Medicine

Analysis of KEYNOTE-A18 Trial Finds Keytruda is Not Cost-Effective at Current Prices

adminMarch 9, 2025

Credit: stas_malyarevsky | stock.adobe.com A cost-effectiveness analysis of results from the Phase III ENGOT-cx11/GOG-3407/KEYNOTE-A18 clinical trial (NCT04221945) found that the addition…

Phase III Trials Confirm Remibrutinib Effectively Reduces Chronic Spontaneous Urticaria Symptoms
Medicine

Phase III Trials Confirm Remibrutinib Effectively Reduces Chronic Spontaneous Urticaria Symptoms

adminMarch 9, 2025

Credit: ABUL | stock.adobe.com Findings from the Phase III REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) clinical trials show that remibrutinib reduces…

MATTERHORN Trial Shows Imfinzi Plus Chemotherapy Produces Significant Event-Free Survival Gains in Resectable Gastric & GEJ Cancer
Medicine

MATTERHORN Trial Shows Imfinzi Plus Chemotherapy Produces Significant Event-Free Survival Gains in Resectable Gastric & GEJ Cancer

adminMarch 8, 2025March 8, 2025

Credit: Crystal light | stock.adobe.com Results from the Phase III MATTERHORN trial (NCT04592913) found that perioperative treatment with Imfinzi (durvalumab)…

Leveraging Technology for Efficient Trial Design
Medicine

Leveraging Technology for Efficient Trial Design

adminMarch 8, 2025

Image Credit: © putilov_denis – stock.adobe.com Clinical trials are becoming increasingly complex, with trial cycle times rising by over 30%…

Ensuring the Long-Term Effectiveness of Clinical Trials
Medicine

Ensuring the Long-Term Effectiveness of Clinical Trials

adminMarch 7, 2025

In a recent video interview with Applied Clinical Trials, Iddo Peleg, CEO and co-founder at Yonalink, discussed the impact of…

Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
Medicine

Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial

adminMarch 7, 2025March 7, 2025

Image Credit: © photon_photo – stock.adobe.com Tris Pharma has announced positive, topline results from its ALLEVIATE-2 Phase III clinical trial…

Opportunities Amidst Recent Research Policy Challenges
Medicine

Opportunities Amidst Recent Research Policy Challenges

adminMarch 6, 2025

In a recent video interview with Applied Clinical Trials, Iddo Peleg, CEO and co-founder at Yonalink, discussed the impact of…

Increasing Clinical Trial Diversity with a Satellite Model
Medicine

Increasing Clinical Trial Diversity with a Satellite Model

adminMarch 6, 2025

In a recent video interview with Applied Clinical Trials, Iddo Peleg, CEO and co-founder at Yonalink, discussed the impact of…

Legal and Political Implications of the NIH Funding Freeze
Medicine

Legal and Political Implications of the NIH Funding Freeze

adminMarch 5, 2025

ACT: With some judges indicating that the NIH funding freeze may be illegal, are there grounds for the NIH to…

The Impact of NIH Funding Cuts and Diversity Bans on Research and Talent Retention
Medicine

The Impact of NIH Funding Cuts and Diversity Bans on Research and Talent Retention

adminMarch 5, 2025

ACT: In addition to the NIH funding cuts, how do you see the clinical trials industry navigating other political challenges,…

Making Clinical Trials More Accessible in Light of Recent FDA, NIH Policy Changes
Medicine

Making Clinical Trials More Accessible in Light of Recent FDA, NIH Policy Changes

adminMarch 4, 2025March 4, 2025

In a recent video interview with Applied Clinical Trials, Iddo Peleg, CEO and co-founder at Yonalink, discussed the impact of…

Adapting to Funding Shifts and Policy Challenges
Medicine

Adapting to Funding Shifts and Policy Challenges

adminMarch 4, 2025

ACT: What should stakeholders have top of mind as they find new ways to effectively navigate and continue medical research?…

Positive Results from CheckMate -8HW Trial Lead to Priority Review, Breakthrough Therapy Designation for Opdivo Plus Yervoy in MSI-H/dMMR Colorectal Cancer
Medicine

Positive Results from CheckMate -8HW Trial Lead to Priority Review, Breakthrough Therapy Designation for Opdivo Plus Yervoy in MSI-H/dMMR Colorectal Cancer

adminMarch 3, 2025March 3, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com Positive findings from the ongoing Phase III CheckMate -8HW trial (NCT04008030) resulted in the FDA granting…

GEMSTONE-303 Trial Shows Sugemalimab Plus Chemotherapy Significantly Improves Survival in Advanced Gastric Cancer
Medicine

GEMSTONE-303 Trial Shows Sugemalimab Plus Chemotherapy Significantly Improves Survival in Advanced Gastric Cancer

adminMarch 3, 2025March 3, 2025

Credit: David A Litman | stock.adobe.com Results from the Phase III GEMSTONE-303 trial (NCT03802591) show that sugemalimab combined with chemotherapy…

Three Ways AI is Revolutionizing Clinical Development
Medicine

Three Ways AI is Revolutionizing Clinical Development

adminMarch 2, 2025

Image Credit: © Egor – stock.adobe.com Artificial intelligence (AI) is the biggest transformation in life sciences in the last 25…

PRESTIGE-AF Trial Shows DOACs Reduce Ischemic Stroke Risk in Intracerebral Hemorrhage Survivors, Heighten Bleeding Complications
Medicine

PRESTIGE-AF Trial Shows DOACs Reduce Ischemic Stroke Risk in Intracerebral Hemorrhage Survivors, Heighten Bleeding Complications

adminMarch 2, 2025March 2, 2025

Credit: magicmine | stock.adobe.com Results from the Phase III PRESTIGE-AF trial (NCT03996772) found that treatment with direct oral anticoagulants (DOACs)…

Opdualag Misses Primary Endpoint in Phase III RELATIVITY-098 Trial for Melanoma
Medicine

Opdualag Misses Primary Endpoint in Phase III RELATIVITY-098 Trial for Melanoma

adminMarch 1, 2025

Credit: Ocskay Mark | stock.adobe.com The Phase III RELATIVITY-098 trial (NCT05002569) of Opdualag (nivolumab and relatlimab-rmbw) in the adjuvant treatment…

AI and Digital Technology in Regulatory Submissions
Medicine

AI and Digital Technology in Regulatory Submissions

adminMarch 1, 2025March 1, 2025

Credit: Tierney | stock.adobe.com The pharmaceutical industry is making significant strides driven by digital innovation and artificial intelligence (AI). As…

Potential Updates to FDA’s Protocol Deviations Guidance
Medicine

Potential Updates to FDA’s Protocol Deviations Guidance

adminFebruary 28, 2025

In a recent video interview with Applied Clinical Trials, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, discussed FDA’s…

NIH Partially Lifts Hold on Medical Funding
Medicine

NIH Partially Lifts Hold on Medical Funding

adminFebruary 28, 2025

Image Credit: © Tada Images – stock.adobe.com The National Institutes of Health (NIH) has partially lifted a freeze on its…

Strategies for Embedding Protocol Flexibility
Medicine

Strategies for Embedding Protocol Flexibility

adminFebruary 27, 2025February 27, 2025

In a recent video interview with Applied Clinical Trials, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, discussed FDA’s…

Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey
Medicine

Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey

adminFebruary 27, 2025

Sponsored by uMotif In this video, uMotif CEO Steve Rosenberg discusses key trends shaping the clinical trial landscape, including CRO…

Reinforcing Quality by Design in Clinical Trials
Medicine

Reinforcing Quality by Design in Clinical Trials

adminFebruary 26, 2025

In a recent video interview with Applied Clinical Trials, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, discussed FDA’s…

New Data Emerges from Phase IIb RELIEVE UCCD Study in Ulcerative Colitis and Crohn’s Disease
Medicine

New Data Emerges from Phase IIb RELIEVE UCCD Study in Ulcerative Colitis and Crohn’s Disease

adminFebruary 26, 2025

Image Credit: © Sebastian Kaulitzki – stock.adobe.com Teva and Sanofi have shared additional data from the Phase IIb RELIEVE UCCD…

Vera Pomerantseva of eClinical Solutions Reacts to FDA’s Recent Protocol Deviations Guidance
Medicine

Vera Pomerantseva of eClinical Solutions Reacts to FDA’s Recent Protocol Deviations Guidance

adminFebruary 25, 2025

In a recent video interview with Applied Clinical Trials, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, discussed FDA’s…

Shakthi Kumar Talks Real-World Data Use in Clinical Development
Medicine

Shakthi Kumar Talks Real-World Data Use in Clinical Development

adminFebruary 25, 2025

ACT: Could you share real-world use cases where this technology has significantly accelerated clinical development, improved data integrity, or optimized…

Smarter Clinical Asset Evaluation Powered by Causal Machine Learning
Medicine

Smarter Clinical Asset Evaluation Powered by Causal Machine Learning

adminFebruary 24, 2025

Credit: WrightStudio | stock.adobe.com It is an old story in the pharmaceutical world. Every year, countless drugs are developed at…

Accelerate Inclusive Enrollment and Delivery with Lightship
Medicine

Accelerate Inclusive Enrollment and Delivery with Lightship

adminFebruary 24, 2025

Lightship focuses on patient accessibility and centricity in clinical trials, ensuring the patient experience is a positive one. Learn more…

Final Analysis of CheckMate -816 Trial Shows Opdivo Plus Chemotherapy Boosts Overall Survival in Resectable NSCLC
Medicine

Final Analysis of CheckMate -816 Trial Shows Opdivo Plus Chemotherapy Boosts Overall Survival in Resectable NSCLC

adminFebruary 23, 2025February 23, 2025

Credit: Sebastian Kaulitzki | stock.adobe.com A final analysis of survival data from the Phase III CheckMate -816 trial (NCT02998528) showed…

Sebastien Coppe Discusses Advancing Innovation in Clinical Trials
Medicine

Sebastien Coppe Discusses Advancing Innovation in Clinical Trials

adminFebruary 23, 2025

ACT: You were a part of panel discussion on start-up companies. Can you briefly discuss what the panel entailed? Coppe:…

Best Practices for Reducing Risk Upfront in a Clinical Trial
Medicine

Best Practices for Reducing Risk Upfront in a Clinical Trial

adminFebruary 22, 2025February 22, 2025

In a recent video interview with Applied Clinical Trials, Dominique Demolle, CEO of Cognivia, discussed challenges in improving patient adherence…

ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis
Medicine

ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis

adminFebruary 22, 2025

Credit: Saiful52 | stock.adobe.com Results from the Phase III ASTRO trial (NCT05528510) found that treatment with subcutaneous (SC) Tremfya (guselkumab;…

Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence
Medicine

Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence

adminFebruary 21, 2025

ACT: What are Phastar’s key objectives for attending SCOPE 2025, and how do you see the conference shaping discussions on…

Phase III AMPLIFY Trial Shows Calquence Plus Venetoclax Significantly Improves Survival in Untreated CLL
Medicine

Phase III AMPLIFY Trial Shows Calquence Plus Venetoclax Significantly Improves Survival in Untreated CLL

adminFebruary 21, 2025February 21, 2025

Credit: jarun011 | stock.adobe.com A regimen of fixed-duration Calquence (acalabrutinib; AstraZeneca) plus venetoclax, with or without Gazyva (obinutuzumab), was found to…

Using AI/ML to Improve Patient Adherence
Medicine

Using AI/ML to Improve Patient Adherence

adminFebruary 20, 2025

In a recent video interview with Applied Clinical Trials, Dominique Demolle, CEO of Cognivia, discussed challenges in improving patient adherence…

The Impact of Non-Adherence on Study Protocols
Medicine

The Impact of Non-Adherence on Study Protocols

adminFebruary 20, 2025

In a recent video interview with Applied Clinical Trials, Dominique Demolle, CEO of Cognivia, discussed challenges in improving patient adherence…

The Importance of Real-World Evidence in Medical Research and Drug Development
Medicine

The Importance of Real-World Evidence in Medical Research and Drug Development

adminFebruary 19, 2025February 19, 2025

Credit: putilov_denis | stock.adobe.com Introduction As the gold standard for clinical research, randomized controlled trials (RCTs) are central to scientific…

Samuel Salvaggio Discusses Crucial Partnerships for Trial Efficiency
Medicine

Samuel Salvaggio Discusses Crucial Partnerships for Trial Efficiency

adminFebruary 19, 2025

ACT: What types of partnerships—whether with CROs, technology vendors, or patient advocacy groups—do you see as crucial for improving trial…

Improving Patient Adherence
Medicine

Improving Patient Adherence

adminFebruary 18, 2025

In a recent video interview with Applied Clinical Trials, Dominique Demolle, CEO of Cognivia, discussed challenges in improving patient adherence…

Samuel Salvaggio Discusses One2Treat’s Primary Objectives for Attending SCOPE
Medicine

Samuel Salvaggio Discusses One2Treat’s Primary Objectives for Attending SCOPE

adminFebruary 18, 2025February 18, 2025

ACT: What are your primary objectives for attending SCOPE 2025, and what insights are you hoping to gain regarding trial…

AI/ML’s Impact in Patient Care
Medicine

AI/ML’s Impact in Patient Care

adminFebruary 17, 2025February 17, 2025

ACT: At the end of the day, it has to matter how these artificial intelligence/machine learning (AI/ML)-driven solutions are aiding…

Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)
Medicine

Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)

adminFebruary 17, 2025February 17, 2025

February 3rd 2025 Article This white paper presents findings from the PurpleLab Migraine Study, which leverages real-world data to analyze…

Implementing Diversity, Equity, and Inclusion in Drug Development
Medicine

Implementing Diversity, Equity, and Inclusion in Drug Development

adminFebruary 16, 2025

February 13, 2025 Publication Video Sponsored Jennifer Kim, PhD, assistant research professor, Tufts School of Medicine, Tufts Center for the…

Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
Medicine

Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial

adminFebruary 16, 2025

Credit: Juan Gärtner | stock.adobe.com Results of the multinational Phase II eNRGy trial (NCT02912949) show that zenocutuzumab (Bizengri) produced durable…

Updated TALAPRO-2 Trial Data Confirms Talzenna Plus Xtandi Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Medicine

Updated TALAPRO-2 Trial Data Confirms Talzenna Plus Xtandi Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer

adminFebruary 15, 2025

Credit: Dr_Microbe | stock.adobe.com Updated data from the final analysis of the Phase III TALAPRO-2 trial (NCT03395197) show a statistically…

SCOPE Summit 2025: Outlook on Clinical Data
Medicine

SCOPE Summit 2025: Outlook on Clinical Data

adminFebruary 15, 2025February 15, 2025

ACT: With Veeva’s 2025 Clinical Data Trend Report now available, what are some key trends in clinical data that you’re…

Lightship’s Approach to Accessible, Inclusive, and Impactful Clinical Trials
Medicine

Lightship’s Approach to Accessible, Inclusive, and Impactful Clinical Trials

adminFebruary 14, 2025

Lightship focuses on patient accessibility and centricity in clinical trials, ensuring the patient experience is a positive one. Learn more…

Clinical Research, DEI Initiatives Caught in Political Headwinds Amidst Funding Freeze
Medicine

Clinical Research, DEI Initiatives Caught in Political Headwinds Amidst Funding Freeze

adminFebruary 14, 2025

Image Credit: © WESTOCK – stock.adobe.com The clinical research industry finds itself at a crossroads, faced with difficult decisions amid…

Posts navigation

Older posts
Newer posts

Recent Posts

  • Can a Sexual harassment lawyer negotiate compensation?
  • What is a purple team assessment in cybersecurity?
  • Can I schedule weekly Home Cleaning Service Toronto?
  • What compensation is available in unjust dismissal Canada?
  • Which buyers visit global sources fair yearly?
  • 구글 검색 누락 업데이트 때문인가요?
  • How to choose the best customer success staffing agencies?
  • 후기는 강남달토가 전반적으로 좋은 편이야?
  • 강남 가라오케 가격 비교 해봤어요?
  • What if arguments increase in a long distance relationship?
  • 강남호빠는 예약이 필수인가요?
  • Is weekend service available for KitchenAid Repair Bay Area?
  • How much does an employment lawyer Toronto cost?
  • Does the TikTok API support webhooks?
  • Can I get mobile car detailing in Bristol?
  • Do HVAC inspections identify safety hazards in Bermuda Dunes CA?
  • How to request beats earbud replacement?
  • Spotting “Blue Chip” Protocols with the Decen Masters Framework
  • Does a Locksmith near me handle commercial lock systems?
  • Can termination pay obligations be insured by employers?

Archives

  • July 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023

Categories

  • Arts Entertainments
  • Auto
  • Business
  • Cryptocurrency
  • Digital Marketing
  • Education
  • Finance
  • Gaming
  • Health Fitness
  • Home Kitchen
  • Legal Law
  • Lifestyle Fashion
  • Medicine
  • Pets
  • Real Estate
  • Relationship
  • Shopping Product Reviews
  • Sports
  • Technology
  • Tours Travel
Slot
Slot
Copyright © 2026 Isierige.com | News Port by Ascendoor | Powered by WordPress.